Acquired Resistance to PD-1/PD-L1 Blockade in Lung Cancer: Mechanisms and Patterns of Failure
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Acquired Resistance to PD-1/PD-L1 Blockade in Lung Cancer: Mechanisms and Patterns of Failure
Authors
Keywords
-
Journal
Cancers
Volume 12, Issue 12, Pages 3851
Publisher
MDPI AG
Online
2020-12-21
DOI
10.3390/cancers12123851
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Immunoactivating the tumor microenvironment enhances immunotherapy as predicted by integrative computational model
- (2020) Aleksander S. Popel PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Tumor heterogeneity and clonal cooperation influence the immune selection of IFN-γ-signaling mutant cancer cells
- (2020) Jason B. Williams et al. Nature Communications
- Targeting Myeloid-Derived Suppressor Cell, a Promising Strategy to Overcome Resistance to Immune Checkpoint Inhibitors
- (2020) Aohan Hou et al. Frontiers in Immunology
- Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy
- (2019) Tuba N. Gide et al. CANCER CELL
- Restriction of PD-1 function by cis-PD-L1/CD80 interactions is required for optimal T cell responses
- (2019) Daisuke Sugiura et al. SCIENCE
- The negative impact of antibiotics on outcomes in cancer patients treated with immunotherapy: a new independent prognostic factor?
- (2019) A Elkrief et al. ANNALS OF ONCOLOGY
- Patterns of failure after immunotherapy with checkpoint inhibitors predict durable progression-free survival after local therapy for metastatic melanoma
- (2019) Nicholas D. Klemen et al. Journal for ImmunoTherapy of Cancer
- Treg-mediated acquired resistance to immune checkpoint inhibitors
- (2019) Reem Saleh et al. CANCER LETTERS
- Immune Checkpoint Inhibitor Outcomes for Patients With Non–Small-Cell Lung Cancer Receiving Baseline Corticosteroids for Palliative Versus Nonpalliative Indications
- (2019) Biagio Ricciuti et al. JOURNAL OF CLINICAL ONCOLOGY
- Antibiotic use and the efficacy of immune checkpoint inhibitors in cancer patients: a pooled analysis of 2740 cancer patients
- (2019) Xuan-Zhang Huang et al. OncoImmunology
- Association of Prior Antibiotic Treatment With Survival and Response to Immune Checkpoint Inhibitor Therapy in Patients With Cancer
- (2019) David J. Pinato et al. JAMA Oncology
- Site‐specific response patterns, pseudoprogression, and acquired resistance in patients with melanoma treated with ipilimumab combined with anti–PD‐1 therapy
- (2019) Ines Pires da Silva et al. CANCER
- Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer
- (2018) L Derosa et al. ANNALS OF ONCOLOGY
- Mechanisms of resistance to immune checkpoint inhibitors
- (2018) Russell W Jenkins et al. BRITISH JOURNAL OF CANCER
- Inhibition of the adenosine A2a receptor modulates expression of T cell coinhibitory receptors and improves effector function for enhanced checkpoint blockade and ACT in murine cancer models
- (2018) Robert D. Leone et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA
- (2018) Sarah B. Goldberg et al. CLINICAL CANCER RESEARCH
- Regulation and Function of the PD-L1 Checkpoint
- (2018) Chong Sun et al. IMMUNITY
- Clinical Features and Management of Acquired Resistance to PD-1 Axis Inhibitors in 26 Patients With Advanced Non–Small Cell Lung Cancer
- (2018) Scott N. Gettinger et al. Journal of Thoracic Oncology
- STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma
- (2018) Ferdinandos Skoulidis et al. Cancer Discovery
- Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non–Small-Cell Lung Cancer
- (2018) Kathryn C. Arbour et al. JOURNAL OF CLINICAL ONCOLOGY
- Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC?
- (2018) Andrea Botticelli et al. Journal of Translational Medicine
- Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma
- (2018) Noam Auslander et al. NATURE MEDICINE
- Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
- (2018) Spencer C. Wei et al. Cancer Discovery
- A positive correlation between the EZH2 and PD-L1 expression in resected lung adenocarcinomas
- (2018) Gouji Toyokawa et al. ANNALS OF THORACIC SURGERY
- Targeting Adenosine Receptor Signaling in Cancer Immunotherapy
- (2018) Kevin Sek et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- 89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer
- (2018) Frederike Bensch et al. NATURE MEDICINE
- Targeting indoleamine-2,3-dioxygenase in cancer: Scientific rationale and clinical evidence
- (2018) Biagio Ricciuti et al. PHARMACOLOGY & THERAPEUTICS
- Noncoding regions are the main source of targetable tumor-specific antigens
- (2018) Céline M. Laumont et al. Science Translational Medicine
- Peripheral Blood TCR Repertoire Profiling May Facilitate Patient Stratification for Immunotherapy against Melanoma
- (2018) Sabrina A. Hogan et al. Cancer Immunology Research
- iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
- (2017) Lesley Seymour et al. LANCET ONCOLOGY
- Chromatin states define tumour-specific T cell dysfunction and reprogramming
- (2017) Mary Philip et al. NATURE
- In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target
- (2017) Robert T. Manguso et al. NATURE
- T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition
- (2017) Enfu Hui et al. SCIENCE
- Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients
- (2017) V. Gopalakrishnan et al. SCIENCE
- Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
- (2017) Bertrand Routy et al. SCIENCE
- In vivo imaging reveals a tumor-associated macrophage–mediated resistance pathway in anti–PD-1 therapy
- (2017) Sean P. Arlauckas et al. Science Translational Medicine
- Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer
- (2017) Scott Gettinger et al. Cancer Discovery
- Clinical and molecular features of innate and acquired resistance to anti-PD-1/PD-L1 therapy in lung cancer
- (2017) Shalin Shah et al. Oncotarget
- Metagenomic Shotgun Sequencing and Unbiased Metabolomic Profiling Identify Specific Human Gut Microbiota and Metabolites Associated with Immune Checkpoint Therapy Efficacy in Melanoma Patients
- (2017) Arthur E. Frankel et al. NEOPLASIA
- Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade
- (2016) K. E. Pauken et al. SCIENCE
- Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
- (2016) Shohei Koyama et al. Nature Communications
- Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations
- (2016) Daniel Sanghoon Shin et al. Cancer Discovery
- Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non–Small Cell Lung Cancer
- (2016) Valsamo Anagnostou et al. Cancer Discovery
- PD-1 Blockade Expands Intratumoral Memory T Cells
- (2016) A. Ribas et al. Cancer Immunology Research
- IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer
- (2015) K Abiko et al. BRITISH JOURNAL OF CANCER
- Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression
- (2015) Chih-Hao Chang et al. CELL
- Myeloid-derived suppressor cell impact on endogenous and adoptively transferred T cells
- (2015) Ainhoa Arina et al. CURRENT OPINION IN IMMUNOLOGY
- The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?
- (2015) Daniel Sanghoon Shin et al. CURRENT OPINION IN IMMUNOLOGY
- Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy
- (2015) A. Sivan et al. SCIENCE
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- Immune evasion in cancer: Mechanistic basis and therapeutic strategies
- (2015) Dass S. Vinay et al. SEMINARS IN CANCER BIOLOGY
- Adenosine Receptor 2A Blockade Increases the Efficacy of Anti–PD-1 through Enhanced Antitumor T-cell Responses
- (2015) Paul A. Beavis et al. Cancer Immunology Research
- Extracellular Adenosine-Mediated Modulation of Regulatory T Cells
- (2014) Akio Ohta et al. Frontiers in Immunology
- Commensal Bacteria Control Cancer Response to Therapy by Modulating the Tumor Microenvironment
- (2013) N. Iida et al. SCIENCE
- Cancer Genome Landscapes
- (2013) B. Vogelstein et al. SCIENCE
- Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells
- (2013) S. Spranger et al. Science Translational Medicine
- A CD38/CD203a/CD73 ectoenzymatic pathway independent of CD39 drives a novel adenosinergic loop in human T lymphocytes
- (2013) Alberto L Horenstein et al. OncoImmunology
- Tumor Evasion from T Cell Surveillance
- (2011) Katrin Töpfer et al. JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY
- Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+T cell dysfunction in melanoma patients
- (2010) Julien Fourcade et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Blockade of B7-H1 or B7-DC induces an anti-tumor effect in a mouse pancreatic cancer model
- (2009) Miura INTERNATIONAL JOURNAL OF ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started